Table 2. Demographic data of patients (n=385) who underwent mitral valve surgery (2016–2020) that were discussed at mitral MDT meeting compared with those who underwent surgery but were not discussed at mitral MDT meeting.
|
MDT (n=310) |
No MDT (n=75) |
p |
|
|---|---|---|---|
|
Mean age ± SD, years |
66 ± 12 |
64 ± 13 |
0.344 |
|
Female, n (%) Male, n (%) |
116 (38) 194 (62) |
29 (39) 46 (61) |
0.030 |
|
Median BMI (IQR), kg/m2 |
26 (24–29) |
26 (22–29) |
0.457 |
|
Urgent/emergent, n (%) |
55 (18) |
63 (84) |
<0.001 |
|
Median NYHA (IQR) |
3 (2–4) |
4 (3–4) |
<0.001 |
|
Diabetes mellitus (oral therapy/insulin), 29 (9) n (%) |
29(9) |
1 (23) |
0.002 |
|
Atrial fibrillation/flutter, n (%) |
114 (37) |
21 (28) |
0.114 |
|
Extra-cardiac arteriopathy, n (%) |
14 (5) |
4 (5) |
0.768 |
|
TIA/CVA, n (%) |
48 (16) |
8 (11) |
0.852 |
|
Good LV function (LVEF ≥50%), n (%) |
216 (70) |
50 (67) |
0.748 |
|
Moderate LV function (LVEF 30–49%), n (%) |
81 (26) |
19 (25) |
0.876 |
|
Poor LV function (LVEF <30%), n (%) |
8 (3) |
6 (8) |
0.281 |
|
Moderate pulmonary hypertension, n (%) |
31 (10) |
12 (16) |
0.142 |
|
Severe pulmonary hypertension, n (%) |
39 (13) |
16 (21) |
0.053 |
|
Chronic lung disease, n (%) |
52 (17) |
15 (20) |
0.429 |
|
Poor mobility, n (%) |
1 (0.3) |
7 (9) |
0.101 |
|
Median CrCl (IQR), ml/min |
78 (60–100) |
63 (45–99) |
0.027 |
|
Median EuroSCORE 2 (IQR), % |
2.0 (1.2–4.5) |
6.8 (1.2–14.3) |
0.621 |
Key: BMI = body mass index; CrCl = creatinine clearance; CVA = cerebrovascular accident; IQR = interquartile range; LV = left ventricular; LVEF = left ventricular ejection fraction; MDT = multi-disciplinary team; NYHA = New York Heart Association; SD = standard deviation; TIA = transient ischaemic attack